Replies to post #13133 on Bioelectronics Corp (BIEL)

[Brabo]

On a positive note...

Being re-imbursable in the Netherlands is all together a positive point, i.e. the product has become a mainstream drug. However, major acceptance might be an issue for a (long/some ?) while. Also, volumes in the Dutch market will never make BIEL a really big company.
The point is that the Dutch distributor is doing a good job (see also the miracle stories about the healing diabetes wounds), while this contrasts sharply with the poor job BIEL is doing in their home market (just to name a few: poor PR, scrappy design and/or packaging, working together with shady people like JN...need I go on ???)

Therefor ending on a negative note...
Unless BIEL starts working professionally we're a long way off the hoped-for levels in PPS